The amount of dextran in PLGA nanocarriers modulates protein corona and promotes cell membrane damage

J Mater Chem B. 2022 Oct 19;10(40):8282-8294. doi: 10.1039/d2tb01296k.

Abstract

Polymeric nanocarriers (NCs) are efficient vehicles to prevent drug unspecific biodistribution and increase the drug amounts delivered to tumor tissues. However, some toxicological aspects of NCs still lack a comprehensive assessment, such as their effects on cellular processes that lead to toxicity. We evaluate the interaction of poly(lactic-co-glycolic acid) (PLGA) NCs prepared using dextran (Dex) and Pluronic®-F127 as stabilizing agents with myocardial cells (H9C2), breast adenocarcinoma cells (MCF-7) and macrophages (RAW 264.7) to address the effect of Dex in PLGA NC formulations. By an emulsion diffusion method, doxorubicin-loaded NCs were prepared with no Dex (PLGA-DOX), 1% (w/v) Dex (Dex1/PLGA-DOX) and 5% (w/v) Dex (Dex5/PLGA-DOX). Uptake analyses revealed a significant reduction in Dex5/PLGA-DOX NC uptake by H9C2 and MCF-7, as in the case of Dex1/PLGA-DOX NCs in the absence of in vitro protein corona, revealing an effect of dextran concentration on the formation of protein corona. RAW 264.7 cells presented a greater uptake of Dex5/PLGA-DOX NCs than the other NCs likely because of receptor mediated endocytosis, since C-type lectins like SIGN-R1, mannose receptors and scavenger receptor type 1 that are expressed in RAW 264.7 can mediate Dex uptake. Despite the lower uptake, Dex5/PLGA-DOX NCs promote the generation of reactive oxygen species and oxidative membrane damage in MCF-7 and H9C2 even though cellular metabolic activity assessed by MTT was comparable among all the NCs. Our results highlight the importance of an in-depth investigation of the NC-cell interaction considering additional mechanisms of damage apart from metabolic variations, as nanoparticle-induced damage is not limited to imbalance in metabolic processes, but also associated with other mechanisms, e.g., membrane and DNA damage.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antineoplastic Agents* / pharmacology
  • Cell Membrane / metabolism
  • Dextrans
  • Doxorubicin / metabolism
  • Doxorubicin / pharmacology
  • Drug Carriers / metabolism
  • Emulsions / metabolism
  • Excipients / metabolism
  • Humans
  • Lectins, C-Type / metabolism
  • Poloxamer / metabolism
  • Polylactic Acid-Polyglycolic Acid Copolymer / metabolism
  • Protein Corona*
  • Reactive Oxygen Species / metabolism
  • Tissue Distribution

Substances

  • Polylactic Acid-Polyglycolic Acid Copolymer
  • Dextrans
  • Protein Corona
  • Drug Carriers
  • Antineoplastic Agents
  • Poloxamer
  • Emulsions
  • Excipients
  • Reactive Oxygen Species
  • Doxorubicin
  • Lectins, C-Type